Targeted delivery of cytotoxic proteins to prostate cancer via conjugation to small molecule urea-based PSMA inhibitors
Abstract Prostate cancer cells are characterized by a remarkably low proliferative rate and the production of high levels of prostate-specific proteases. Protein-based toxins are attractive candidates for prostate cancer therapy because they kill cells via proliferation-independent mechanisms. Howev...
Guardado en:
Autores principales: | O. C. Rogers, D. M. Rosen, L. Antony, H. M. Harper, D. Das, X. Yang, I. Minn, R. C. Mease, M. G. Pomper, S. R. Denmeade |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9ccc999bbc6e4ef58648953c074fc96c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A prostate-specific membrane antigen (PSMA)-targeted prodrug with a favorable in vivo toxicity profile
por: Srikanth Boinapally, et al.
Publicado: (2021) -
Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy
por: Zhu Q, et al.
Publicado: (2011) -
Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer
por: Kristin A. Plichta, et al.
Publicado: (2021) -
Impact of the molar activity and PSMA expression level on [18F]AlF-PSMA-11 uptake in prostate cancer
por: Sarah Piron, et al.
Publicado: (2021) -
Quantitative [Fe]MRI of PSMA-targeted SPIONs specifically discriminates among prostate tumor cell types based on their PSMA expression levels
por: Sillerud LO
Publicado: (2016)